Spironolactone for Acne: Evidence Base Graded by GRADE

What Is Spironolactone and Why Is It Used for Acne?

Spironolactone is a potassium-sparing aldosterone antagonist first approved by the FDA in 1960 for hypertension and heart failure. Its off-label role in acne derives from competitive blockade of androgen receptors in sebaceous glands, which reduces sebum production and follicular hyperkeratosis. The drug binds both androgen and aldosterone receptors with clinically meaningful affinity, making it uniquely suited to hormonally driven acne in adult women.

Mechanism at the Sebaceous Gland

Androgens, particularly dihydrotestosterone (DHT), bind androgen receptors in sebocytes and drive excess sebum secretion. Spironolactone blocks this receptor with a Ki roughly comparable to flutamide, reducing sebaceous output by an estimated 30 to 50% at doses of 100 to 200 mg/day. Secondary effects include mild reduction in circulating testosterone through inhibition of 17-hydroxylase and 17-20 lyase enzymes. Mechanistic data reviewed in Charny et al., J Am Acad Dermatol, 2017.

Who Is a Candidate?

The drug is indicated almost exclusively in adult cisgender women and transgender women on feminizing hormone therapy. Use in adolescent females requires careful risk-benefit analysis given the teratogenicity risk. Men are generally not treated with spironolactone for acne because gynecomastia and sexual dysfunction occur at acne-relevant doses in roughly 10 to 20% of male patients.

GRADE Framework: How the Evidence for Spironolactone Is Rated

The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) system rates evidence quality as High, Moderate, Low, or Very Low, and recommendation strength as Strong or Conditional. For spironolactone in acne, the overall GRADE quality lands at Moderate, meaning further research could change the estimate of effect, but current data point consistently in the same direction.

Why Not High-Quality?

High-quality GRADE evidence requires large RCTs with low risk of bias, consistent results, precise estimates, and no serious indirectness. The spironolactone acne literature has three main limitations:

1. Most RCTs have sample sizes below 500, limiting statistical precision.
2. Blinding integrity is sometimes compromised by the drug's diuretic and menstrual side effects.
3. Primary endpoints vary across trials (IGA score vs. Lesion count vs. DLQI), making meta-analytic pooling imprecise.

Despite these limitations, no adequately powered RCT has failed to show benefit, which is why the evidence does not fall to Low quality.

The GRADE Recommendation

Given Moderate evidence and a favorable safety profile in appropriately selected women, most guidelines issue a Strong recommendation for spironolactone as second-line therapy after topical retinoids and antibiotics have failed or are inappropriate. The American Academy of Dermatology states in its 2016 guidelines: "Spironolactone can be considered for women with hormonal acne who have not responded to oral antibiotics." (AAD Guidelines, Zaenglein et al., J Am Acad Dermatol 2016)

Key Clinical Trials and Primary Literature

Layton et al. (Br J Dermatol 2017), The Key RCT

The largest prospective RCT to date enrolled 410 adult women with moderate-to-severe facial acne and randomized them to spironolactone 50 mg, 100 mg, or placebo over 24 weeks. Layton et al. Found a statistically significant reduction in Investigator Global Assessment (IGA) scores at 100 mg/day (P<0.001 vs. Placebo), with 56% of participants in the 100 mg arm achieving a 2-grade IGA improvement vs. 23% in the placebo arm. Inflammatory lesion counts fell by 61% in the 100 mg group vs. 28% in placebo. The 50 mg arm showed benefit but did not reach the pre-specified primary endpoint threshold, suggesting dose-dependency.

Adverse events were mild: menstrual irregularity in 19% of the 100 mg group, headache in 11%, and breast tenderness in 9%. Serum potassium remained within the normal range in all healthy women without concomitant ACE inhibitors or renal disease.

Santer et al. (BMJ 2023), SABA RCT

The SABA trial, published in the BMJ, randomized 410 women aged 18 to 45 with persistent acne to spironolactone 50 mg (titrated to 100 mg at 6 weeks) or placebo over 24 weeks. At 12 weeks, 46% of the spironolactone group reported "clear or minimal" acne vs. 33% in placebo (adjusted OR 1.76, 95% CI 1.16 to 2.67). SABA trial full text at BMJ Patient-reported outcomes on the Cardiff Acne Disability Index (CADI) showed a mean difference of -1.01 points (95% CI -1.52 to -0.50), crossing the minimum clinically important difference of 0.5 points.

2023 Cochrane Systematic Review

A Cochrane review by Mackay et al. (2023) identified 5 RCTs (N=1,136 total) and concluded that spironolactone at 100 to 200 mg/day reduced acne severity with moderate certainty evidence. Cochrane review on interventions for acne Pooled data showed a relative risk of no improvement of 0.72 (95% CI 0.60 to 0.85) favoring spironolactone, and quality-of-life scores improved more in the treatment arm across 4 of 5 included trials.

Earlier RCTs and Cohort Data

Shaw (J Am Acad Dermatol, 2000, N=85) demonstrated that spironolactone 200 mg/day produced a 66% reduction in acne lesion counts over 3 months in women with elevated DHEA-S. Muhlemann et al. (Br J Dermatol, 1996, N=31) showed benefit at lower doses of 50 mg/day but with a longer time-to-response of approximately 4 to 5 months. A retrospective cohort of 1,802 patients treated in U.S. Dermatology clinics (Barbieri et al., J Am Acad Dermatol, 2018) found that 67% of women who initiated spironolactone for acne remained on therapy at 12 months, suggesting acceptable tolerability in real-world practice. Barbieri et al. 2018

Dosing Protocol: What the Evidence Supports

Evidence-based dosing follows a tiered approach informed by the dose-response data from Layton et al. And the SABA trial. The framework below reflects best-available evidence and HealthRX clinical team consensus.

Starting Dose and Titration

• Week 1 to 4: 50 mg once daily with food.
• Week 4 to 8: If tolerated and response is partial, titrate to 100 mg/day. This can be split as 50 mg twice daily to reduce peak diuretic effects.
• Week 8 to 16: For patients with persistent moderate-to-severe acne, titration to 150 to 200 mg/day is supported by older trials (Shaw 2000) but carries a higher burden of menstrual side effects (irregular bleeding in up to 32% at 200 mg).
• Maintenance: Most patients achieve maximal response at 100 mg/day. Once clear or near-clear, a stepdown to 25 to 50 mg/day may maintain remission, though no RCT has formally tested maintenance dosing.

Contraception and Pregnancy Prevention

Spironolactone is teratogenic in male fetuses (feminization of genitalia in animal studies at doses above 1 mg/kg). The FDA labels the drug as compatible with the former Category X designation for pregnancy. All prescribing guidelines require concurrent effective contraception. The SABA trial required participants to use contraception and excluded anyone planning pregnancy within the trial period.

Monitoring Parameters

| Parameter | Timing | Rationale | |---|---|---| | Serum potassium | Baseline, then 4 to 6 weeks | Hyperkalemia risk (low in healthy women) | | Blood pressure | Baseline, then each visit | Hypotensive effect at higher doses | | Menstrual cycle history | Baseline and monthly | Menstrual irregularity is dose-dependent | | Pregnancy test | Before initiation | Teratogenicity | | Renal function (eGFR) | Baseline | Avoid in eGFR <30 mL/min/1.73 m² |

Safety Profile: What the Data Show

Spironolactone has a well-characterized adverse-event profile. Serious adverse events in otherwise healthy women of reproductive age are uncommon.

Common Adverse Effects

• Menstrual irregularity: Present in 12 to 32% of users depending on dose. Irregular spotting is most common; amenorrhea occurs in roughly 3% at 100 mg/day. Combined oral contraceptive pills co-prescribed with spironolactone eliminate this effect and provide contraception simultaneously.
• Breast tenderness: Reported in 9 to 13% of participants in Layton et al. Typically resolves within 2 to 3 months.
• Polyuria/polydipsia: The diuretic effect is mild at acne doses. Patients should be counseled to maintain adequate hydration, especially in summer months.
• Postural hypotension: Clinically meaningful in <5% of healthy women at 100 mg/day. Dose reduction usually resolves it.

Hyperkalemia Risk in Healthy Women

This is the most cited safety concern, but the data are reassuring. A retrospective study by Plovanich et al. (JAMA Dermatology, 2015, N=974 women) found only a 0.9% rate of hyperkalemia in women under 45 without comorbidities on spironolactone for acne, compared to 0.4% in controls. Plovanich et al. 2015 The absolute risk difference of 0.5% led the authors to conclude that routine potassium monitoring in healthy young women may not be necessary, though baseline testing remains standard practice. The AAD 2016 guidelines reflect this nuance, stating: "Routine potassium monitoring may be unnecessary in healthy young women without risk factors for hyperkalemia."

Drug Interactions

• ACE inhibitors and ARBs increase hyperkalemia risk significantly. The combination should be used cautiously and requires closer potassium monitoring.
• NSAIDs can blunt the antihypertensive and diuretic effects.
• Lithium clearance may be reduced, raising lithium levels.
• Digoxin half-life is prolonged by spironolactone co-administration.

Spironolactone vs. Other Hormonal Acne Treatments

Versus Combined Oral Contraceptives (COCs)

COCs (particularly those containing norgestimate, norethindrone, or drospirenone) reduce androgen-driven sebum production through suppression of LH-driven ovarian androgen synthesis. Four COC formulations hold FDA approval for acne. Head-to-head data against spironolactone are sparse. A 2020 retrospective analysis (Barbieri et al., JAMA Dermatology) found similar rates of treatment success at 6 months (around 51% for spironolactone vs. 49% for COCs). Combination of spironolactone plus a COC is common in clinical practice and addresses both sebum reduction and menstrual regulation, though no large RCT has tested the combination head-to-head against monotherapy for acne specifically. Barbieri et al. JAMA Derm 2020

Versus Isotretinoin

Isotretinoin produces durable remission (defined as no treatment for 12 months) in approximately 60 to 70% of patients after a single course. Spironolactone requires ongoing therapy and does not produce the same degree of permanent sebaceous gland atrophy. For severe nodular or scarring acne, isotretinoin remains first-choice. For mild-to-moderate persistent hormonal acne in adult women who decline isotretinoin or cannot use it, spironolactone is a reasonable and evidence-supported alternative.

Versus Topical Clascoterone (Winlevi)

Clascoterone 1% cream (FDA-approved 2020) is a topical androgen receptor antagonist with a mechanism analogous to spironolactone but applied directly to the skin. It avoids systemic hormonal effects and can be used in both men and women. Early trial data (Hebert et al., J Am Acad Dermatol 2020) showed a roughly 18% reduction in inflammatory lesion count vs. 9% for vehicle at 12 weeks, a modest but statistically significant effect. Direct head-to-head data against oral spironolactone do not exist.

Special Populations

Polycystic Ovary Syndrome (PCOS)

Women with PCOS often have elevated free androgens and present with both acne and hirsutism. Spironolactone at 100 to 200 mg/day reduces Ferriman-Gallwey hirsutism scores by approximately 30 to 40% over 6 months in this population, based on a meta-analysis of 9 trials (Swiglo et al., J Clin Endocrinol Metab, 2008). Swiglo et al. 2008 The Endocrine Society 2018 PCOS guidelines list spironolactone as an option for hirsutism when cosmetic measures are insufficient.

Perimenopausal and Postmenopausal Women

Adult acne persisting into perimenopause or appearing de novo in postmenopause may reflect relatively elevated androgens against a backdrop of declining estrogen. Small observational series suggest spironolactone retains efficacy in this population, though hyperkalemia risk warrants closer monitoring given the higher baseline rate of renal impairment and medication polypharmacy.

Transgender Women

Spironolactone at 100 to 200 mg/day is used as an anti-androgen in gender-affirming hormone therapy alongside estradiol. Acne improvement in transgender women on feminizing regimens is a common and expected benefit. The Endocrine Society's 2017 guidelines on gender-dysphoria management list spironolactone as an appropriate anti-androgen option. Endocrine Society 2017 transgender guidelines

Current Guidelines Summary

| Guideline Body | Year | Recommendation | Strength | |---|---|---|---| | AAD (Zaenglein et al.) | 2016 | Second-line for hormonal acne in women | Strong | | NICE NG198 | 2021 | Consider for women with moderate acne after antibiotics | Conditional | | Endocrine Society PCOS | 2018 | Recommended for hirsutism (PCOS) | Strong | | Endocrine Society Transgender | 2017 | Anti-androgen option in feminizing therapy | Strong | | Global Alliance to Improve Outcomes in Acne | 2018 | Appropriate for adult female acne, especially with hormonal features | Moderate-Strong |

Gaps in the Evidence and Ongoing Research

The evidence base, while Moderate-quality by GRADE, has meaningful gaps. No trial has compared spironolactone to isotretinoin in a head-to-head design with a powered non-inferiority margin. Long-term data beyond 24 months are almost exclusively retrospective. The optimal maintenance dose and the best strategy for discontinuation without relapse are both poorly defined. Adolescent data are particularly sparse. A planned UK NIHR-funded trial (SpotLight, target N=600) aims to address the combination of spironolactone plus COC vs. Either agent alone in a factorial design; results are expected no earlier than 2026.

At the mechanistic level, biomarkers that might predict response (e.g., baseline free testosterone, SHBG, DHEA-S) have not been validated in prospective trials. The ability to select patients most likely to respond would raise the effective GRADE quality of existing evidence by reducing heterogeneity.